<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131244</url>
  </required_header>
  <id_info>
    <org_study_id>HU0616</org_study_id>
    <nct_id>NCT04131244</nct_id>
  </id_info>
  <brief_title>In Vitro Follicle Activation in Patient With Premature Ovarian Failure Under 36 Years Old</brief_title>
  <official_title>In Vitro Follicle Activation of Dormant Follicles in Patient With Premature Ovarian Failure Under 36 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Marianna University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hacettepe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial that the investigators aim to validate In-vitro Activation (IVA)
      treatment protocol, which was previously defined by Kazuhiro Kawamura (MD) and Aaron Hsueh
      (PhD), in Turkish patient with Premature Ovarian Insufficiency (POI) under age 36.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study is as following;

        -  Validation of the previously defined In-Vitro Activation Protocol approach in Turkish
           patients under 36 years old with Premature Ovarian Insufficiency (POI).

        -  Giving an opportunity to young POI patient in Turkey for having genetically own baby.

        -  Primary outcome measure would be live birth.

        -  For activation of primordial follicles, phosphatase and tensin homolog (PTEN) inhibitor
           and protein kinase B (AKT) stimulator will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome is live birth, defined as the delivery of a live-born infant at 24 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle growth rate</measure>
    <time_frame>1 year</time_frame>
    <description>Number of ovulation induction cycle achieved to growth follicle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M-II oocyte rate</measure>
    <time_frame>1 year</time_frame>
    <description>Number of mature oocyte rate among retrieved oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 2-3 good quality embryo rate</measure>
    <time_frame>1 year</time_frame>
    <description>Good quality embryo rate of fertilized oocytes (2PN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
    <description>A clinical pregnancy is a pregnancy that is confirmed by both high levels of human chorionic gonadotropin (hCG) and ultrasound confirmation of a gestational sac or heartbeat (fetal pole)</description>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Activation of Primordial Follicles</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator</intervention_name>
    <description>After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.</description>
    <other_name>Laparoscopic unilateral oophorectomy</other_name>
    <other_name>Laparoscopic auto grafting of ovarian cortex fragments sub-peritoneally</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with POI

          -  Short amenorrhea period (1 - 2 years)

        Exclusion Criteria:

          -  Having been treated with chemotherapy and/or radiotherapy;

          -  Having been diagnosed with advanced stage of endometriosis (endometriomas)

          -  Having been diagnosed with the chronic diseases such as diabetes, cardiac failure,
             kidney insufficiency, morbid obesity etc..

          -  Presence of chromosomal abnormality (Turner, Fragile-X etc.)

          -  Previous multiple laparotomies

          -  Menopause &gt;10 years

          -  Accompanied azoospermia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hacettepe University School of Medicine, Department of Ob/Gyn</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hacettepe University</investigator_affiliation>
    <investigator_full_name>Sezcan Mumusoglu</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

